# Study of ST-1898 in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Cancer

Source: https://onco.cc/trials/nct06359847/  
OnCo record `nct06359847` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of ST-1898 tablets in thyroid cancer, run by Beijing Scitech-Mq Pharmaceuticals Limited, now recruiting.

## Summary

Study of ST-1898 in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Cancer is a phase 2 interventional study registered as NCT06359847 by Beijing Scitech-Mq Pharmaceuticals Limited, with 60 participants planned, started 2023-11-15 and due to reach its primary completion in 2027-12. Interventions recorded: ST-1898 tablets.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06359847
- Phase: 2
- Setting: A Multicenter, Phase II Clinical Trial to Evaluate the Efficacy and Safety of ST-1898 Tablets in Patients With Locally Advanced or Metastatic RAIR-DTC After Failure of at Least First-line TKI Systemic Therapy
- Sponsor: Beijing Scitech-Mq Pharmaceuticals Limited
- Enrolled: 60

## Sources

- ClinicalTrials.gov NCT06359847: https://clinicaltrials.gov/study/NCT06359847

## Connected records

- cancers: [Thyroid cancer](https://onco.cc/cancers/thyroid/)
- companies: [Beijing Scitech-Mq Pharmaceuticals](https://onco.cc/companies/beijing-scitech-mq-pharmaceuticals/)

---
JSON: https://onco.cc/api/v1/entities/nct06359847.json